Montrouge, France, July 10 (22:30 CET) 2023
Half-year report on the DBV T echnologies liquidity contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq: DBVT), a French biopharmaceutical laboratory, today publishes the half-year report of its liquidity contract with ODDO BHF.
Under the liquidity contract entrusted to ODDO BHF, relating to the shares of DBV TECHNOLOGIES, on June 30, 2023, the following resources appeared in the liquidity account:
149,972 DBV Technologies shares,
When the contract is set up, from 1
July 2018, the following resources appeared in the liquidity account:
41,159 DBV Technologies shares,
Over the period from 01/01/2023 to 06/30/2023, were executed:
1326 purchase transactions,
1213 sales transactions.
Over this same period, the volumes traded represented:
432,837 shares and 1,330,080 euros for purchase,
432,658 shares and 1,355,257 euros for sale.
About DBV Technologies
DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).
Source link -86